142 related articles for article (PubMed ID: 25449654)
1. Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.
Suttle AB; Grossmann KF; Ouellet D; Richards-Peterson LE; Aktan G; Gordon MS; LoRusso PM; Infante JR; Sharma S; Kendra K; Patel M; Pant S; Arkenau HT; Middleton MR; Blackman SC; Botbyl J; Carson SW
J Clin Pharmacol; 2015 Apr; 55(4):392-400. PubMed ID: 25449654
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites.
Ouellet D; Gibiansky E; Leonowens C; O'Hagan A; Haney P; Switzky J; Goodman VL
J Clin Pharmacol; 2014 Jun; 54(6):696-706. PubMed ID: 24408395
[TBL] [Abstract][Full Text] [Related]
3. Concomitant oral and intravenous pharmacokinetics of dabrafenib, a BRAF inhibitor, in patients with BRAF V600 mutation-positive solid tumors.
Denton CL; Minthorn E; Carson SW; Young GC; Richards-Peterson LE; Botbyl J; Han C; Morrison RA; Blackman SC; Ouellet D
J Clin Pharmacol; 2013 Sep; 53(9):955-61. PubMed ID: 23846776
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the effect of dabrafenib and metabolites on QTc interval in patients with BRAF V600-mutant tumours.
Nebot N; Arkenau HT; Infante JR; Chandler JC; Weickhardt A; Lickliter JD; Sarantopoulos J; Gordon MS; Mak G; St-Pierre A; Tang L; Mookerjee B; Carson SW; Hayes S; Grossmann KF
Br J Clin Pharmacol; 2018 Apr; 84(4):764-775. PubMed ID: 29243287
[TBL] [Abstract][Full Text] [Related]
5. The metabolic drug-drug interaction profile of Dabrafenib: in vitro investigations and quantitative extrapolation of the P450-mediated DDI risk.
Lawrence SK; Nguyen D; Bowen C; Richards-Peterson L; Skordos KW
Drug Metab Dispos; 2014 Jul; 42(7):1180-90. PubMed ID: 24748562
[TBL] [Abstract][Full Text] [Related]
6. Effects of particle size, food, and capsule shell composition on the oral bioavailability of dabrafenib, a BRAF inhibitor, in patients with BRAF mutation-positive tumors.
Ouellet D; Grossmann KF; Limentani G; Nebot N; Lan K; Knowles L; Gordon MS; Sharma S; Infante JR; Lorusso PM; Pande G; Krachey EC; Blackman SC; Carson SW
J Pharm Sci; 2013 Sep; 102(9):3100-9. PubMed ID: 23608920
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the Effects of Repeat-Dose Dabrafenib on the Single-Dose Pharmacokinetics of Rosuvastatin (OATP1B1/1B3 Substrate) and Midazolam (CYP3A4 Substrate).
Nebot N; Won CS; Moreno V; Muñoz-Couselo E; Lee DY; Gasal E; Bouillaud E
Clin Pharmacol Drug Dev; 2021 Sep; 10(9):1054-1063. PubMed ID: 33932130
[TBL] [Abstract][Full Text] [Related]
8. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
[TBL] [Abstract][Full Text] [Related]
9. Prediction of the Transporter-Mediated Drug-Drug Interaction Potential of Dabrafenib and Its Major Circulating Metabolites.
Ellens H; Johnson M; Lawrence SK; Watson C; Chen L; Richards-Peterson LE
Drug Metab Dispos; 2017 Jun; 45(6):646-656. PubMed ID: 28320730
[TBL] [Abstract][Full Text] [Related]
10. Dose selection, pharmacokinetics, and pharmacodynamics of BRAF inhibitor dabrafenib (GSK2118436).
Falchook GS; Long GV; Kurzrock R; Kim KB; Arkenau HT; Brown MP; Hamid O; Infante JR; Millward M; Pavlick A; Chin MT; O'Day SJ; Blackman SC; Curtis CM; Lebowitz P; Ma B; Ouellet D; Kefford RF
Clin Cancer Res; 2014 Sep; 20(17):4449-58. PubMed ID: 24958809
[TBL] [Abstract][Full Text] [Related]
11. Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure.
Rowland A; van Dyk M; Hopkins AM; Mounzer R; Polasek TM; Rostami-Hodjegan A; Sorich MJ
Clin Pharmacol Ther; 2018 Dec; 104(6):1219-1228. PubMed ID: 29574693
[TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib.
Puszkiel A; Noé G; Bellesoeur A; Kramkimel N; Paludetto MN; Thomas-Schoemann A; Vidal M; Goldwasser F; Chatelut E; Blanchet B
Clin Pharmacokinet; 2019 Apr; 58(4):451-467. PubMed ID: 30094711
[TBL] [Abstract][Full Text] [Related]
13. Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.
Menzies AM; Long GV
Clin Cancer Res; 2014 Apr; 20(8):2035-43. PubMed ID: 24583796
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
Sarantopoulos J; Mita AC; Wade JL; Morris JC; Rixe O; Mita MM; Dedieu JF; Wack C; Kassalow L; Lockhart AC
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1113-24. PubMed ID: 25307552
[TBL] [Abstract][Full Text] [Related]
15. Dabrafenib inhibits ABCG2 and cytochrome P450 isoenzymes; potential implications for combination anticancer therapy.
Sorf A; Vagiannis D; Ahmed F; Hofman J; Ceckova M
Toxicol Appl Pharmacol; 2022 Jan; 434():115797. PubMed ID: 34780725
[TBL] [Abstract][Full Text] [Related]
16. Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.
Tornio A; Neuvonen PJ; Niemi M; Backman JT
Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):83-95. PubMed ID: 27548563
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and disposition of oral dabrafenib in cancer patients: proposed participation of aryl nitrogen in carbon-carbon bond cleavage via decarboxylation following enzymatic oxidation.
Bershas DA; Ouellet D; Mamaril-Fishman DB; Nebot N; Carson SW; Blackman SC; Morrison RA; Adams JL; Jurusik KE; Knecht DM; Gorycki PD; Richards-Peterson LE
Drug Metab Dispos; 2013 Dec; 41(12):2215-24. PubMed ID: 24097902
[TBL] [Abstract][Full Text] [Related]
18. Successful Treatment of Metastatic Adult Wilms Tumor With Anti-BRAF Treatment: A Case Report and a Brief Review of the Literature.
de Vries-Brilland M; Sionneau B; Dutriaux C; Blay JY; Ravaud A; Gross-Goupil M
Clin Genitourin Cancer; 2019 Aug; 17(4):e721-e723. PubMed ID: 31109800
[No Abstract] [Full Text] [Related]
19. BRAF inhibitor activity in V600R metastatic melanoma.
Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
[TBL] [Abstract][Full Text] [Related]
20. Effect of co-administration of ketoconazole, a strong CYP3A inhibitor, on the pharmacokinetics, safety and tolerability of navitoclax, a first-in-class oral Bcl-2 family inhibitor, in cancer patients.
Salem AH; Yang J; Graham A; Patnaik A; Holen K; Pradhan R; Xiong H
Anticancer Res; 2014 Apr; 34(4):2001-6. PubMed ID: 24692738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]